This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Slides:

Advertisements

Similar presentations

Four Known Types of MS Clinically isolated syndrome (CIS)

Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Systemic Lupus Erythematosus

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Psoriasis Treatments

Highlights From the 2017 Annual European MS Meeting

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Recognizing and Staging the Severity of NASH: What Tools Do We Have?

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Progression After Cancer Immunotherapy in Advanced NSCLC

New Therapies in Alzheimer's Disease

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Early Dementia Distinguishing AD From MCI

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Current and Future Goals in the Treatment of Relapsed CLL

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

New Data in nAMD: What Does the Future Hold?

Navigating the Data and Evolving Our Approach

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Assessing Disease Progression in MS Treatment

Management Challenges in CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Hyperhidrosis Is Burdensome!

Navigating New Oral Treatment Algorithms in CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Personalizing Management in the Care of Patients With Advanced Sarcoma

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Talking With Your Patients About Excessive Sweating

Getting to Grips With the Science of CGRP and Migraine

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Tackling Schizophrenia With Your Patients

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Wearing Off in Parkinson Disease: The Value of New Generation COMT Inhibition.

Real-World Evidence: What Is It and Why Is It so Important In MS?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

The Psychiatrist's Role in Tardive Dyskinesia

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Peanut Allergy Immunotherapy

Updates in SMA From an International Muscle Meeting

The Acne Landscape Is Evolving

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

MRD Analysis in Chronic Lymphocytic Leukemia

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

Next-Generation Sequencing and ctDNA

A New Era in Migraine Prevention

Understanding the Role of Disability in MS Management

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Presentation transcript:

The Blurred Line Between RRMS and SPMS: Can Novel Tools Bring SPMS Diagnosis Into Focus?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

MS Subtypes and Clinical Course

Detecting Disease Activity

Characteristic Signs and Symptoms of SPMS

Detecting Progression to SPMS

Challenges in Detecting and Measuring Progression

Treatments and Indications for SPMS

Recent RCTs in SPMS

Defining Endpoints When Measuring Progression

Biomarkers in Use or Development in MS: Identifying or Predicting Progression

Focal Cord and Brain Lesions in RRMS and SPMS

Neurofilament Light Chain as a Marker of Progression

A Tool to Define SPMS: Lorscheider Tool

Clinical History for Detecting Progression

Web-Based MS Progression Discussion Tool

MS Progression Discussion Tool: Clinical Information to Input, Parts 1 and 2

MS Progression Discussion Tool: Clinical Information to Input, Parts 1, 2, and 3

Development Process for the Tool: Ability to Differentiate Between RRMS and SPMS

Using the Tool: Next Steps

Case 1: 45-Year-Old Policeman With Clear Signs of SPMS

Case 1: Quality of Life and Emotional State

Case 2: A 35-Year-Old Teacher

Case 2: Quality of Life and Emotional State

MS Progression Discussion Tool: Page 1, Patient and Disease Characteristics

Page 2, Signs and Symptoms

Page 3, Impact of Symptoms

MS Progression Discussion Tool: Page 4, Results

Practical Application of the Tool: Future Perspectives

Additional Considerations: Patient Feedback

Comparison With Other Tools in SPMS

Abbreviations